Homepage > Company > Media > Pharma News > 2022 > AbbVie’s Skyrizi Wins FDA Approval for Psoriatic Arthritis

AbbVie’s Skyrizi Wins FDA Approval for Psoriatic Arthritis

The FDA has approved AbbVie’s Skyrizi (risankizumab-rzaa) for treating adults with psoriatic arthritis, an inflammatory disease that afflicts an estimated 30 percent of psoriasis sufferers.

The drug was previously FDA-approved in April 2019 for treating moderate-to-severe plaque psoriasis in adults.

The approval was supported by two phase 3 studies showing Skyrizi significantly improved symptoms, such as swollen, tender and painful joints after 24 weeks of treatments.

Skyrizi works by blocking the inflammatory IL-23 cytokine which has been linked with several chronic immune-mediated diseases. The drug was previously FDA-approved in April 2019 for treating moderate-to-severe plaque psoriasis in adults.

Part of a partnership between Boehringer Ingelheim and AbbVie, Skyrizi is being developed and commercialised by AbbVie worldwide.

January 25, 2022

https://www.fdanews.com/

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...